Leukemic stem cell differentiation visible at single-cell resolution in AML patients treated with BRG1/BRM inhibitor FHD286MOLECULAR CANCER THERAPEUTICSIF5.52023-12-010PRE
Establishing the cellular and molecular impacts of the dual BRM/BRG1 inhibitor FHD-286 on pre-clinical models of non-small cell lung cancer (NSCLC)MOLECULAR CANCER THERAPEUTICSIF5.52023-12-010PRE
The dual BRG1/BRM (SMARCA4/2) inhibitor FHD-286 induces functional differentiation and splicing defects in preclinical models of acute myeloid leukemia (AML)MOLECULAR CANCER THERAPEUTICSIF5.52023-12-010PRE
The dual BRM/BRG1 (SMARCA2/4) inhibitor FHD-286 induces differentiation in preclinical models of AMLCANCER RESEARCHIF16.62023-04-042PRE
YAP1 and WWTR1 expression inversely correlates with neuroendocrine markers in Merkel cell carcinomaJOURNAL OF CLINICAL INVESTIGATIONIF13.62023-03-017OAAI
Merkel Cell Carcinoma Sensitivity to EZH2 Inhibition Is Mediated by SIX1 DerepressionJOURNAL OF INVESTIGATIVE DERMATOLOGYIF5.72022-10-0111OAAI
Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinomaJOURNAL OF CLINICAL INVESTIGATIONIF13.62022-07-0122OAAI
Critical role for cholesterol in Lassa fever virus entry identified by a novel small molecule inhibitor targeting the viral receptor LAMP1PLOS PATHOGENSIF4.92018-09-2818OAAI